Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here are two links with pictures as requested:
Predictive Technology Group's CEO Bradley Robinson in Hong Kong, September 10 to 13, 2019, PRED Labs Visit 11-12-2019
Predictive Technologies Group, Inc. CEO Bradley Robinson being shown where newly listed companies "Ring The Bell" at NASDAQ, New York City August 15, 2019
Bradley Robinson wanted to demonstrate his support for the company; he is a major PRED shareholder. However, PRED's Board consists of seasoned public company executives, and they can not be expected to do the same. Indeed, if the Board members did buy PRED shares, PRED's D&O insurance company would quite likely take issue and substantially increase PRED's annual premium. That is correct; PRED has D&O insurance from one of the most significant underwriters in the U.S.
Jerry Kramer, has not sued PRED, I spoke with Jerry today and this was news to him as well!!!
Best to all,
Thomas
It is my understanding that Ferguson and or his beneficiary have signed lock-up agreements, and I am not aware of Ken Ward having sold any shares recently and he too has signed a share lock-up agreement.
If PRED's Board members or management has knowledge of Material Nonpublic Information that would have a significant change of the assets and or revenue of the company, information that would substantially impact the value of the stock, they can not acquire shares based on that Material Nonpublic Information. If they acquired shares and the value significantly increased by their just having Material Nonpublic Information, they would be in trouble with the SEC and would have violated their individual fiduciary duty to PRED and its shareholders.
Thus the information which the Board and management possess, if disclosed would very likely influence a reasonable investor’s decision to purchase or sell an issuer’s securities.
I was with the Board in New York and I know many would buy if the could.
Insider Trading and Securities Fraud Enforcement Act of 1988
The GE example you provided is not relative to PRED.
Besides, PRED's management and the Board have all signed lock-up agreements that specifically prevent them from selling PRED shares, e.g., they can sell up to 1% of their holdings per month.
FYI, I nor we have not sold any PRED shares.
Wake up, they (the Board of Directors and key management) can not buy PRED shares because they have inside information.
They know what's going on, nor can they sell shares per the lock-up agreements they all signed.
The shares are being bought, however, a big share vacuum sucking sound...lol.
The ARTguide Market and Revenue:
The market revenue from ARTguide is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.;
Survey data indicates all fertility clinics are interested in ARTguide;
A significant percentage (35 to 40%) of those clinics will order the ARTguide test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.
Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which produces over $3.3 billion in annual revenue.
There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide in the U.S.
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).
https://asrmcongress.org/
Consider PRED's U.S. and internationally patented ARTguide diagnostic is being launched on the market at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.
https://www.rightdiagnosis.com/e/endometriosis/stats-country.htm
PRED's Near Term Market Cap?
Use the below PE, and note there are many other companion proprietary gene diagnostics and therapeutics in PRED's pipeline but let's just consider the multiples for ARTguide.
See my post No. 14572 for chart.
Dr. Ken Ward holding hundreds of women's DNA from PRED's 340,000+ Women's DNA Library, one of, if not the world's largest women's DNA banks. The entire gene library is duplicated at another secured site (beyond the geologic fault-line) in Colorado.
Dr Ward holding DNA from worlds largest women's largest DNA Bank
https://www.predictivelabs.com/team
https://www.globalbankingandfinance.com/category/news/juneau-biosciences-presents-new-genetic-discoveries-in-endometriosis-at-asrm-scientific-congress-expo/amp/
Jerry Kramer has purchased more shares in PRED.
The link below is a picture of Jerry Kramer yesterday. During our meeting, Jerry told me he has purchased more shares in PRED.
Jerry Kramer, Nov 17 2019
Many on this blog have personally spoken with me, joined me on LinkedIn, and stay in contact.
Nov. 13, 2019, PRED Board of Directors and Guest Dinner at the Havard Club, New York City, CLSA/CITIC labs tour November 12, 2019, ARTguide and other PRED diagnostics foreign markets planning break-out sessions during PRED's BOD/management meetings at Wilson Sonsini Goodrich Rosati's offices, New York City, November 11 to 14th, 2019.
https://photos.app.goo.gl/ZBxvsUqzo3tpRwxC7
Wilson Sonsini Goodrich Rosati
We carried out due diligence on the litigation cited which was settled. It's obvious that Robinson did, in fact, have a relationship with Walgreens as evidenced by Tim Lacy having joined PRED. PRED also has a global collaboration with the Preeclampsia Foundation (a PATH-Gates beneficiary) and entered into collaboration post-Hindenburg after having carried out an investigation. CLSA also conducted an equally intrusive due-diligence investigation of all PRED Directors and management, exceeding NASDAQ and FINRA.
Most on this blog do no comprehended Chinese cuisine and have no insight to the multiple dishes now on PRED's menu.
Those who believe CLSA/CITIC is a biopharmaceutical and diagnostics match-maker dating service for western companies entering China are myopic and need perspective counseling.
I wonder how Indian and Middle Eastern cuisine will digest when accompanied by PRED's ingredients? Perhaps CLSA has operations in other world regions?
I fly home tomorrow after an eventful week in New York. We had insightful discussions with John Sorrentino and PRED's other directors. Our foreign guests equally enjoyed their visit to PRED's labs in Salt Lake and their interactions here in New York with PRED management, directors, attorneys, and others. The highlight for me was multiple meetings with world-class scientists and PRED's equally talented IP attorneys from WSGR.
Sadly, my two girls will be disappointed because I failed to purchase JoJo accessories from the American Girl flagship store in Rockefeller Center.
https://www.americangirl.com/
PRED will be presenting new research at the Endometriosis World Congress in Shanghai
https://endometriosis.ca/world-congress/wce2020/
I have not vanished nor sold any PRED shares. I have been requested not to post on the boards and have been very occupied.
Last week I was traveling, and as I write this dispatch, I am sitting in PRED's offices in Salt Lake. We have been swamped speaking with Dr. Ken Ward, touring Predictive Biotech's labs, and PRED's other labs. See the link below.
Exceptional research and product developments are substantial, and fast-paced additions the PRED's portfolio of products and sector opportunities continue to grow as my previous posts anticipated.
Last week I was traveling and enjoyed lovely Chinese take-out in Hong Kong and traveled into China, where I bought some very touching gifts for our two daughters. They were thrilled to receive them upon my return home.
Did I previously tell you China has over 74 million women diagnosed with endometriosis? Perhaps I also said China is the most significant IVF market in the world?
Gosh, I found a wall of State Certifications in PRED's genetics lab, e.g., California, Pennsylvania, Maryland, etc. It seems about fourteen states have independently inspected and approved PRED's labs. See the link below if you are interested is seeing some of those inspection certificates.
In conclusion, the news of my sell-off of PRED shares, my disappearance or death is greatly exaggerated by those that should experience such fate.
PRED Labs Visit 11-12-2019
An uninformed low-information post, silly in scope and knowledge. Juxtaposed to the reality of thousands of active animal and clinical research programs, quite a fantastic foolish post.
https://irp.nih.gov/our-research/scientific-focus-areas/stem-cell-biology
https://www.ninds.nih.gov/Current-Research/Focus-Tools-Topics/Stem-Cell
https://stemcells.nih.gov/research/nih-research/nih-stem-cell-unit.htm
https://commonfund.nih.gov/stemcells
https://stemcells.nih.gov/research/state-research.htm
https://stemcells.nih.gov/research/international.htm
https://www.crg.eu/
https://www.eurostemcell.org/
Here are but a small window into published research, and again all one need to understand PREDs positioning is review prior PR.
Mesenchymal Stem Cells for Regenerative Medicine
Cells. 2019 Aug; 8(8): 886. Published 2019 Aug 13. doi: 10.3390/cells8080886
"MSCs exist in various tissues and organs apart from bone marrow, with multilineage cells from human umbilical cord blood, first reported in early 2000."
"Umbilical cord blood-derived MSCs (UCB-MSCs) exhibit biological advantages relative to other adult sources, including their capability for longer culture times, larger-scale expansion, more significant retardation of senescence, and higher anti-inflammatory effects."
The potential of mesenchymal stem cells derived from amniotic membrane and amniotic fluid for neuronal regenerative therapy
BMB Rep. 2014 Mar; 47(3): 135–140.
"Recently, many studies have identified amniotic fluid (AF) as a new source of MSCs, and these AF-MSCs express the pluripotent marker Oct-4 in almost 90% of the active condition, and they also have multiple differentiation capacity like the AM-MSCs. Further, AF is routinely used to perform the standard evaluation of karyotyping and they are genetic and molecular tested for diagnostic purposes."
Neurodegeneration and Neuro-Regeneration—Alzheimer’s Disease and Stem Cell Therapy
Int J Mol Sci. 2019 Sep; 20(17): 4272. Published 2019 Aug 31. doi: 10.3390/ijms20174272
"Mesenchymal stem cells are multipotent stromal cells that can be isolated from various organs and tissues, such as bone marrow (BM-MSCs), umbilical cord (UCB-MSCs), adipose tissue (AD-MSCs), peripheral blood, amniotic fluid, muscle and lung. MSCs can differentiate into a variety of cells types, are highly proliferative and are easily accessed and easily handled."
"MSCs can also be applied intravenously, as these cells are able to cross the blood-brain barrier and travel to the injury site, which offers enormous benefits for patient treatments."
"Similarly to other types of stem cell transplantation effects, transplantation of MSCs reduced Aß deposits and tau-phosphorylation, increased neurogenesis and provided support with secreted factors and improved learning and memory deficits. Immune modulating and anti-inflammatory effects have also been observed, through the upregulation of neuroprotective and downregulation of pro-inflammatory cytokines."
Embryonic Stem Cell-Derived Mesenchymal Stem Cells (ES-MSCs) Have a Superior Neuroprotective Capacity Over Fetal MSCs in the Hypoxic-Ischemic Mouse Brain.
Stem Cells Transl Med. 2018 May; 7(5): 439–449. Published 2018 Feb 28. doi: 10.1002/sctm.17-0260
"ES-MSCs Have Enhanced Neuroprotective Potential in Comparison to AF-MSCs."
"NF-?B-induced IL-13 production contributes to the increased anti-inflammatory potential of ES-MSC-CM compared with AF-MSC-CM."
Correct, and spot on.
What's going on within PRED's Predictive Biotech
Consider the possibilities:
Mesenchymal Stem Cells for Regenerative Medicine
Cells. 2019 Aug; 8(8): 886. Published 2019 Aug 13. doi: 10.3390/cells8080886
"MSCs exist in various tissues and organs apart from bone marrow, with multilineage cells from human umbilical cord blood, first reported in early 2000."
"Umbilical cord blood-derived MSCs (UCB-MSCs) exhibit biological advantages relative to other adult sources, including their capability for longer culture times, larger-scale expansion, more significant retardation of senescence, and higher anti-inflammatory effects."
The potential of mesenchymal stem cells derived from amniotic membrane and amniotic fluid for neuronal regenerative therapy
BMB Rep. 2014 Mar; 47(3): 135–140.
"Recently, many studies have identified amniotic fluid (AF) as a new source of MSCs, and these AF-MSCs express the pluripotent marker Oct-4 in almost 90% of the active condition, and they also have multiple differentiation capacity like the AM-MSCs. Further, AF is routinely used to perform the standard evaluation of karyotyping and they are genetic and molecular tested for diagnostic purposes."
Neurodegeneration and Neuro-Regeneration—Alzheimer’s Disease and Stem Cell Therapy
Int J Mol Sci. 2019 Sep; 20(17): 4272. Published 2019 Aug 31. doi: 10.3390/ijms20174272
"Mesenchymal stem cells are multipotent stromal cells that can be isolated from various organs and tissues, such as bone marrow (BM-MSCs), umbilical cord (UCB-MSCs), adipose tissue (AD-MSCs), peripheral blood, amniotic fluid, muscle and lung. MSCs can differentiate into a variety of cells types, are highly proliferative and are easily accessed and easily handled."
"MSCs can also be applied intravenously, as these cells are able to cross the blood-brain barrier and travel to the injury site, which offers enormous benefits for patient treatments."
"Similarly to other types of stem cell transplantation effects, transplantation of MSCs reduced Aß deposits and tau-phosphorylation, increased neurogenesis and provided support with secreted factors and improved learning and memory deficits. Immune modulating and anti-inflammatory effects have also been observed, through the upregulation of neuroprotective and downregulation of pro-inflammatory cytokines."
Embryonic Stem Cell-Derived Mesenchymal Stem Cells (ES-MSCs) Have a Superior Neuroprotective Capacity Over Fetal MSCs in the Hypoxic-Ischemic Mouse Brain.
Stem Cells Transl Med. 2018 May; 7(5): 439–449. Published 2018 Feb 28. doi: 10.1002/sctm.17-0260
"ES-MSCs Have Enhanced Neuroprotective Potential in Comparison to AF-MSCs."
"NF-?B-induced IL-13 production contributes to the increased anti-inflammatory potential of ES-MSC-CM compared with AF-MSC-CM."
PRED Hong Kong Press Release "Part One" likely before your AM coffee gets cold. lol
It is always fascinating whom amoung you have connected those dots and see the big picture when all that's required is rereading PRED'S prior Press Announcements and factoring-in that PRED's technologies, directly and indirectly, applies to diagnostics and therapeutics helping more then half of the world's population.
The best is yet to come, from my humble view of course.
Trust you all will have a good day tomorrow and many more days, weeks, and months ahead.
See ThomasHBS-HLS post # 14728 for the basis of ArtGuide (and related) revenue for endometriosis, ART, preeclampsia, and a dozen other indications not yet projected.
No OTCQX listing...that would be silly at this juncture.
Japan has the highest endometriosis per capita of all Asian populations - next stop Tokyo, India, etc.
ARTguide™ Market:
The market revenue from ARTguide™ is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.) and the below data does not include Preeclampsia, ART (IVF), and many other indications;
Survey data indicates all fertility clinics are interested in ARTguide™;
A significant percentage (35 to 40%) of those clinics will order the ARTguide™ test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.
Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide™ diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which generates over $3.3 billion in yearly revenue.
There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide™ in the U.S.
ENDOMETRIOSIS:
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).
PREECLAMPSIA:
Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, and approximately 1.25 million pregnancies in China, causing severe adverse maternal and fetal outcomes, including significant blood loss, organ failure, disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births, and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually worldwide are attributable to preeclampsia. [url]Imprecise diagnostic tools hamper healthcare providers, even in medically advanced countries.
Consider PRED's U.S. and internationally patented ARTguide™ diagnostic is now launched at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.
PRED's management and directors have all signed a share lock-up agreement which is in force for the next two years, this agreement allows for selling up to 1% per month and is on file with PRED's transfer agent. See the 10K for details.
A Closer Look at China’s Supposed Misappropriation of U.S. Intellectual Property
The data show that Chinese royalty payments to the world grew from $1.4 billion in 1999 to $27.2 billion in 2017. In 2016, China ranked fourth in royalty payments to the world, at just under $30 billion, right behind the United States at just over $40 billion.
Chinese royalty payments to the world was $27.2 billion in 2017
Deloitte reviewed the prior audits, and per the 8K, Deloitte will continue to have full access to the former auditor's work product, and in fact, spent time with the former auditors. Seriously, months and months and expenses were required for Deloitte to complete its due diligence review. Deloitte would only become PRED's auditor if all were correct - imagine the liability and litigation Deloitte would face if the SEC filings and financials were not proper.
Surely Deloitte being PRED's auditor, will not only validate PRED in the U.S. but globally.
Deloitte has global offices that can audit PRED's overseas operations if, by chance, there are business units in foreign markets. Reading PRED's previous PR, several mention international patents, and patent applications.
Consider the following language from PRED's 8K:
"The Company has authorized Borgers to respond fully to the inquiries of Deloitte, and Borgers has provided the Company with a letter addressed to the SEC, as required by Item 304(a)(3) of Regulation S-B, that is attached hereto as Exhibit 16.1."
There is not one example of a public life sciences or technology company locking up management and directors shares as suggested. How misleading, so lets say there was a lock-up that the board approved, and if so the board can modify or change the terms at any time. Saying the BOD is sneaky and acting irresponsibly is just smoke and written for another agenda. PREDs Board are not children but rather successful wealthy seasoned world class individuals. PRED's BOD areseated for the long term, let's stop being toddlers.
Connect The Dots: FDA - Cellular & Gene Therapy Products
FDA - Regenerative Medicine Advanced Therapy Designation
If you have only considered PRED's regenerative product applications based on current sales, you are blind to what's really going on in it's labs and global collaborations. Why has PRED significantly increased its physical lab staff, equipment, and patent applications...and then there is Thermo Fisher and PRED Board members who have built and managed tens of billions dollar companies operating in almost every country on Earth.
PRED Directors and Officers' Shares Lock-Up Agreements
ANSWER TO FALSE ALLEGATIONS OF PUMP AND DUMP
FORM 10-K, Item 12:
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
"All shares owned by executive officers and directors of the Company other than those acquired on the open market are subject to lockup agreements. The lockup agreements prevent the sale or transfer of not more than 1% of the covered shares per calendar month until August 2020 without Board approval."
Also, many of the share lock-up agreements were signed months ago.
Consider at the team, the global collaborations, and alignments with accelerating markets - this all requires a world-class team and implementing the strategies.
From experience, I know there are few companies with little to no debt able to scale as quickly as PRED has and will continue to do so.
Shares issued were at that day's closing share price, why would PRED sell shares at a stupid price?
As promised today PRED's 2019 Financials
Apparently, no shareholders on this blog need more validation, it's just one out there solo paddling in class four whitewater, best pull-out for there are rough waters ahead.
Note the investments in labs and equipment.
Perhaps I may be able to provide some clarity to PRED's non-announced activities. PRED has developed and or controls a deep body of intellectual properties (IP) and that IP is of significant value if it becomes protected IP under U.S. and PCT (foreign) patent applications and then prosecuting pending patents into issued patents.
In the U.S., patents are no longer based on "first to invent" but "first to file."
Note that PRED's patent law firm is one of the leading life science and IP law firms in the world. WSGR also has a well-staffed office in Hong Kong.
WSGR Ranked No. 1 in 2017 Life Sciences Law Firm Index
Wilson Sonsini Goodrich Rosati (WSGR)
WSGR The Life Sciences Report - Winter-Spring 2019
WSGR BIOTECH 2019
Perhaps one may consider the amounts of money PRED's has invested in protecting its IP and the associated costs of filing U.S. and international patents.
PRED's financial results may address some of PRED's IP, however, and understandably newly filed patents will not be disclosed nor announced until after their publication 18 months from the patent application date. This non-disclosure is a common practice among life science and technology-centric companies.
Really, not shown any interest in their shareholders - reconsider that the majority of the company is owned and or controlled buy its management and directors.
The company has communicated quite frequently and more than most. I concur and have repeatedly stated all one need do is read PRED's PRs.
You are perhaps correct this next event is known, and therefore my observation and reliance upon "my eyes only" will become established as fact. I stir not in temptations or intrigues upon serious matters. Now the quintessence schedules of civilization are engaged (tick-tock), and final determinant of a pronounced future event accurate or a snare for rabbits and rats. Do have a good weekend.
I will allow you the opportunity to consider and ponder the possibilities, in FACT you have the entire weekend.
In reply to 'cutes' post and OPINION: FACT, the financials are out on Monday.
Wow, you folks are way ahead of reality. I answer a NYSE HK question and all of a sudden PREDs listing in HK. Slow down and consider all that would be involved.
A co-listing in Hong Kong? Gee, I wish I and our team had thought of that.
Are you suggesting PRED does not know about the listing requirements, for I assure they do as I was in a NASDAQ meeting when this was discussed and no one is concerned then or now. The big picture is all any shareholder should be considering.